Latest & greatest articles for measles

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on measles or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on measles and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for measles

1. Measles-mumps-rubella vaccine (MMR): no link with autism

Measles-mumps-rubella vaccine (MMR): no link with autism Prescrire IN ENGLISH - Spotlight ''Measles-mumps-rubella vaccine (MMR): no link with autism'', 1 May 2020 {1} {1} {1} | | > > > Measles-mumps-rubella vaccine (MMR): no link with autism Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Measles-mumps-rubella vaccine (MMR): no link with autism (...) FEATURED REVIEW Studies based on a very significant number of children, taken together, do not show any link between MMR vaccination and the occurrence of autistic disorders. The authors of the two studies claiming the opposite used incorrect data or applied inappropriate analytical methods. Full review (3 pages) available for download by subscribers. Abstract Studies proposing a link between the measles-mumps-rubella vaccine (MMR) and autism were published in 1998 and 2014, and then retracted because

2020 Prescrire

2. Consequences of Undervaccination - Measles Outbreak, New York City, 2018-2019. (Abstract)

Consequences of Undervaccination - Measles Outbreak, New York City, 2018-2019. Measles was declared eliminated in the United States in 2000, but the risk of outbreaks owing to international importations remains. An outbreak of measles in New York City began when one unvaccinated child returned home from Israel with measles; onset of rash occurred on September 30, 2018, 9 days after the child returned home.We investigated suspected cases of measles by conducting interviews, reviewing medical (...) and immunization records, identifying exposed persons, and performing diagnostic testing. Measles-mumps-rubella (MMR) vaccine (given as either MMR or measles-mumps-rubella-varicella vaccine and collectively referred to as MMR vaccine) uptake was monitored with the use of the Citywide Immunization Registry. The total direct cost to the New York City Department of Health and Mental Hygiene was calculated.A total of 649 cases of measles were confirmed, with onsets of rash occurring between September 30, 2018

2020 NEJM

3. National measles guidelines

National measles guidelines National measles guidelines - GOV.UK GOV.UK uses cookies which are essential for the site to work. We also use non-essential cookies to help us improve government digital services. Any data collected is anonymised. By continuing to use this site, you agree to our use of cookies. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance National measles guidelines How to manage cases of suspected measles: what patient details to take, who (...) case of measles is ‘likely’ or ‘unlikely’ case management – what lab tests should be done and the importance of oral fluid testing on all suspected cases measles control – identifying vulnerable contacts and assessing their need for post-exposure prophylaxis Published 28 October 2010 Last updated 2 December 2019 2 December 2019 Added latest version of guidelines. 11 August 2017 Updated to reflect revised clinical advice. 28 October 2010 First published. Related content Collection Explore the topic

2019 Public Health England

4. Practice Advisory: Management of Pregnant and Reproductive-Aged Women during a Measles Outbreak

of reported cases of measles, also known as rubeola, since the disease was eliminated in 2000 1 . Outbreaks have been confirmed in 22 states and the number of cases and their distribution is increasing rapidly. These measles outbreaks have been linked to travelers bringing back cases of measles from other countries. This situation combined with low vaccination coverage among certain communities in the United States leads to pockets of vulnerable communities and contributes to outbreaks such as the one we (...) (GA): CDC; 2019. Available at: . Retrieved April 24, 2019. Centers for Disease Control and Prevention. Measles (rubeola): for healthcare professionals. Atlanta (GA): CDC; 2018. Available at: . Retrieved April 24, 2019. Atmar RL, Englund JA, Hammill H. Complications of measles during pregnancy. Clin Infect Dis 1992;14:217-26. Available at: . Retrieved April 24, 2019. McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary

2019 American College of Obstetricians and Gynecologists

5. Measles: public health response to cases who have travelled by air whilst infectious

Measles: public health response to cases who have travelled by air whilst infectious Measles: public health response to cases who have travelled by air whilst infectious - GOV.UK GOV.UK uses cookies which are essential for the site to work. We also use non-essential cookies to help us improve government digital services. Any data collected is anonymised. By continuing to use this site, you agree to our use of cookies. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search (...) Register by 26 November to vote in the General Election on 12 December. Guidance Measles: public health response to cases who have travelled by air whilst infectious Guidance about infectious measles on a flight (or international travel) for public health staff, passengers and crew. Published 26 June 2012 Last updated 28 October 2019 — From: Documents Ref: PHE gateway number 2018702 If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format

2019 Public Health England

6. What is the role of serologic testing for immunity to measles during an outbreak?

What is the role of serologic testing for immunity to measles during an outbreak? What Is The Role Of Serologic Testing For Immunity To Measles During An Outbreak? – Clinical Correlations Search What Is The Role Of Serologic Testing For Immunity To Measles During An Outbreak? September 18, 2019 6 min read By Sandra Goldlust Peer Reviewed Measles was declared eliminated from the US in 2000. Our country, however, is currently in the midst of the largest measles outbreak since 1992. As of July (...) preschool closures for failure to comply with , 5 and controversial bans on unvaccinated children from entering schools, . 6 Measles is a highly transmissible virus with a basic reproductive number (R 0 ) of 12-18. The R 0 represents the average number of secondary cases resulting from a single primary case in a totally susceptible population. This translates to a need to vaccinate about 93% of the population in order to disrupt measles transmission and achieve herd immunity. 7 Maintaining population

2019 Clinical Correlations

7. Proquad (Measles, Mumps, Rubella and Varicella Virus Vaccine Live)

Proquad (Measles, Mumps, Rubella and Varicella Virus Vaccine Live) Terms of use - Canada.ca Language selection Search Search Canada.ca Search Topics menu Main Menu You are here: Terms of use From These Terms of Use govern the access and use of Clinical Information released by Health Canada for non-commercial purposes. By clicking the button “I agree” and accepting these Terms of Use and upon being granted access to the Clinical Information, you, and, if applicable, the organization on behalf

2019 Health Canada - drugs and medical devices

8. Measles: post-exposure prophylaxis

Measles: post-exposure prophylaxis Measles: post-exposure prophylaxis - GOV.UK GOV.UK uses cookies to make the site simpler. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Research and analysis Measles: post-exposure prophylaxis Guidelines on the use of post-exposure prophylaxis for measles in high-risk groups. Published 1 May 2009 Last updated 4 July 2019 — From: Documents Ref: PHE publications gateway number: GW-492 If you use assistive technology (...) (such as a screen reader) and need a version of this document in a more accessible format, please email . Please tell us what format you need. It will help us if you say what assistive technology you use. Details This guidance summarises the evidence for the effectiveness of post-exposure prophylaxis ( 4 July 2019 Revised guidance. 17 June 2019 Updated guidelines on post-exposure prophylaxis for measles. 11 August 2017 Revised post-exposure prophylaxis guidance: details of changes on page 4. 1 May 2009 First

2019 Public Health England

9. Measles, Mumps, Rubella Vaccination and Autism: A Nationwide Cohort Study. Full Text available with Trip Pro

Measles, Mumps, Rubella Vaccination and Autism: A Nationwide Cohort Study. The hypothesized link between the measles, mumps, rubella (MMR) vaccine and autism continues to cause concern and challenge vaccine uptake.To evaluate whether the MMR vaccine increases the risk for autism in children, subgroups of children, or time periods after vaccination.Nationwide cohort study.Denmark.657 461 children born in Denmark from 1999 through 31 December 2010, with follow-up from 1 year of age and through 31

2019 Annals of Internal Medicine

10. Measles infection

Measles infection Measles infection - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Measles infection Last reviewed: February 2019 Last updated: March 2019 Summary Preventable by immunisation but high levels of coverage are required to prevent outbreaks of disease from occurring. No specific treatment for measles is available except for supportive care. Complications of measles are more common in immunocompromised (...) and poorly nourished individuals and include pneumonia, laryngotracheitis, otitis media, and encephalitis. Definition Measles is a highly infectious disease caused by measles virus, characterised by a maculopapular rash, cough, coryza, conjunctivitis, and a pathognomonic enanthem (Koplik's spots) with an incubation period of about 10 days. History and exam potential exposure to measles unimmunised or vaccine failure fever cough coryza conjunctivitis Koplik's spots maculopapular rash exposure to measles

2019 BMJ Best Practice

11. Management of Pregnant and Reproductive Aged Women during a Measles Outbreak

Control and Prevention. Measles cases and outbreaks. Atlanta (GA): CDC; 2019. Available at: . Retrieved April 24, 2019. Article Locations: Centers for Disease Control and Prevention. Measles (rubeola): for healthcare professionals. Atlanta (GA): CDC; 2018. Available at: . Retrieved April 24, 2019. Article Locations: Atmar RL, Englund JA, Hammill H. Complications of measles during pregnancy. Clin Infect Dis 1992;14:217-26. Available at: . Retrieved April 24, 2019. Article Locations: McLean HQ (...) Management of Pregnant and Reproductive Aged Women during a Measles Outbreak Management of Pregnant and Reproductive Aged Women during a Measles Outbreak | ACOG Clinical Guidance Journals & Publications Patient Education Topics Featured Clinical Topics Hi, Featured Clinical Topics Clinical Guidance Management of Pregnant and Reproductive Aged Women during a Measles Outbreak Practice Advisory April 2019 Jump to Resources Share By reading this page you agree to ACOG's Terms and Conditions

2019 American College of Obstetricians and Gynecologists

12. Measles

Measles Measles | Topics A to Z | CKS | NICE Search CKS… Menu Measles Measles Last revised in March 2018 Measles is a highly contagious airborne infection caused by a morbillivirus of the paramyxovirus family. Diagnosis Management Background information Measles: Summary Measles is a highly contagious airborne infection caused by a morbillivirus of the paramyxovirus family. It infects, via the respiratory tract, nearly all susceptible people who come into contact with it. Once infected (...) , the person develops lifelong immunity. Although endemic in the UK in the past, measles has become relatively rare since the introduction of measles immunization. The main complications of measles are of the respiratory tract or central nervous system and include: Otitis media. Pneumonia, pneumonitis, and tracheobronchitis. Convulsions, encephalitis, and blindness. Subacute sclerosing panencephalitis (a rare but serious complication affecting about 1 in 25,000 people with measles). Measles tends

2019 NICE Clinical Knowledge Summaries

13. Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial. (Abstract)

Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial. Chikungunya fever is an emerging viral disease and substantial threat to public health. We aimed to assess the safety, tolerability, and immunogenicity of a live-attenuated, measles-vectored chikungunya vaccine (MV-CHIK).In this double-blind, randomised, placebo-controlled and active-controlled phase 2 trial, we (...) enrolled healthy volunteers aged 18-55 years at four study sites in Austria and Germany. Participants were randomly assigned to receive intramuscular injections with MV-CHIK (5 × 104 or 5 × 105 50% tissue culture infectious dose), control vaccine, or measles prime and MV-CHIK, in two different administration regimens. Randomisation was done by use of three-digit randomisation codes in envelopes provided by a data management service. The participants and investigators were masked to treatment assignment

2018 Lancet Controlled trial quality: predicted high

14. Measles

Measles Top results for measles - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading (...) history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for measles The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted

2018 Trip Latest and Greatest

15. Evaluation of a Booster Dose of Pentavalent Rotavirus Vaccine Co-Administered with Measles, Yellow Fever and Meningitis A Vaccines in 9-month-old Malian Infants Full Text available with Trip Pro

Evaluation of a Booster Dose of Pentavalent Rotavirus Vaccine Co-Administered with Measles, Yellow Fever and Meningitis A Vaccines in 9-month-old Malian Infants Rotavirus vaccines given to infants are safe and efficacious. A booster dose of rotavirus vaccine could extend protection into the second year of life in low-resource countries.We conducted an open-label, individual-randomized trial in Bamako, Mali. We assigned 600 infants aged 9-11 months to receive measles vaccine (MV), yellow fever

2018 EvidenceUpdates

16. Impact of measles supplementary immunisation activities on utilisation of maternal and child health services in low-income and middle-income countries Full Text available with Trip Pro

Impact of measles supplementary immunisation activities on utilisation of maternal and child health services in low-income and middle-income countries Measles supplementary immunisation activities (SIAs) are an integral component of measles elimination in low-income and middle-income countries (LMICs). Despite their success in increasing vaccination coverage, there are concerns about their negative consequences on routine services. Few studies have conducted quantitative assessments of SIA (...) not appear to significantly impact utilisation of maternal and child services. We find a reduction in care-seeking for treatment of child cough (OR 0.67; 95% CI 0.48 to 0.95); and a few significant effects at the country level, suggesting the need for further investigation of the idiosyncratic effects of SIAs in each country.The paper contributes to the debate on vertical versus horizontal programmes to ensure universal access to vaccination. Measles SIAs do not seem to affect care-seeking for critical

2018 BMJ global health

17. Poverty reduction and equity benefits of introducing or scaling up measles, rotavirus and pneumococcal vaccines in low-income and middle-income countries: a modelling study Full Text available with Trip Pro

Poverty reduction and equity benefits of introducing or scaling up measles, rotavirus and pneumococcal vaccines in low-income and middle-income countries: a modelling study Beyond their impact on health, vaccines can lead to large economic benefits. While most economic evaluations of vaccines have focused on the health impact of vaccines at a national scale, it is critical to understand how their impact is distributed along population subgroups.We build a financial risk protection model (...) to evaluate the impact of immunisation against measles, severe pneumococcal disease and severe rotavirus for birth cohorts vaccinated over 2016-2030 for three scenarios in 41 Gavi-eligible countries: no immunisation, current immunisation coverage forecasts and the current immunisation coverage enhanced with funding support. We distribute modelled disease cases per socioeconomic group and derive the number of cases of: (1) catastrophic health costs (CHCs) and (2) medical impoverishment.In the absence

2018 BMJ global health

18. Measles infection

Measles infection Measles infection - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Measles infection Last reviewed: February 2019 Last updated: March 2019 Summary Preventable by immunisation but high levels of coverage are required to prevent outbreaks of disease from occurring. No specific treatment for measles is available except for supportive care. Complications of measles are more common in immunocompromised (...) and poorly nourished individuals and include pneumonia, laryngotracheitis, otitis media, and encephalitis. Definition Measles is a highly infectious disease caused by measles virus, characterised by a maculopapular rash, cough, coryza, conjunctivitis, and a pathognomonic enanthem (Koplik's spots) with an incubation period of about 10 days. History and exam potential exposure to measles unimmunised or vaccine failure fever cough coryza conjunctivitis Koplik's spots maculopapular rash exposure to measles

2018 BMJ Best Practice

19. Progress towards regional measles elimination – worldwide, 2000–2016 – Progrès accomplis dans le monde en vue de l’élimination régionale de la rougeole, 2000-2016

Progress towards regional measles elimination – worldwide, 2000–2016 – Progrès accomplis dans le monde en vue de l’élimination régionale de la rougeole, 2000-2016 Progress towards regional measles elimination – worldwide, 2000–2016 – Progrès accomplis dans le monde en vue de l’élimination régionale de la rougeole, 2000-2016 JavaScript is disabled for your browser. Some features of this site may not work without it. Toggle navigation Toggle navigation Search Browse Statistics Related Links (...) Progress towards regional measles elimination – worldwide, 2000–2016 – Progrès accomplis dans le monde en vue de l’élimination régionale de la rougeole, 2000-2016 View/ Open View Statistics Altmetrics Share Citation World Health Organization = Organisation mondiale de la Santé . (‎2017)‎. Progress towards regional measles elimination – worldwide, 2000–2016 – Progrès accomplis dans le monde en vue de l’élimination régionale de la rougeole, 2000-2016. Weekly Epidemiological Record = Relevé

2017 WHO

20. Measles virus envelope pseudotyped lentiviral vectors transduce quiescent human HSCs at an efficiency without precedent Full Text available with Trip Pro

Measles virus envelope pseudotyped lentiviral vectors transduce quiescent human HSCs at an efficiency without precedent Hematopoietic stem cell (HSC)-based gene therapy trials are now moving toward the use of lentiviral vectors (LVs) with success. However, one challenge in the field remains: efficient transduction of HSCs without compromising their stem cell potential. Here we showed that measles virus glycoprotein-displaying LVs (hemagglutinin and fusion protein LVs [H/F-LVs]) were capable

2017 Blood advances